Mesothelioma Oral Medication VT3989 Phase 1 Clinical Trial

Get Free Mesothelioma Guide

New Mesothelioma Oral Medication Clinical Trail VT3989

Researchers are currently studying a new promising drug for people with mesothelioma in hopes of moving closer to eliminating tumors. This mesothelioma oral medication is being included in a phase 1, multi-center, open-label study to evaluate the safety, tolerability, and PK of VT3989 in patients with refractory locally advanced or metastatic solid tumors enriched for tumors harboring mutations of the NF2 gene. The gene locks proteins that cause tumors to grow and spread throughout the body. The drug is taken orally and meant for people who have mesothelioma with a mutation in the Neurofibromatosis type 2 (NF2) gene. NF2, a hereditary condition known as acoustic neuromas, are benign tumors that grow on the nerves for balance and hearing in the inner ear.

The trial began in March of 2021 and is estimated to be completed in December of 2024. We understand how suffering from an aggressive disease like mesothelioma can be difficult to live with, and clinical trials give you the chance to have a potential new treatment for mesothelioma before it is widely available. Strict rules are set into place to keep all clinical trial participants safe, but it is important to think about all aspects of the trial, not just the good parts. We want you to feel confident in your decision, so we’ve gathered both the benefits and risks of participating in the trial.

Potential Benefits and Risks of Participating in the VT3989 Clinical Trial

There are many factors for you to consider before participating in clinical trials, such as the VT3989 clinical trial. It is important to consider the benefits and risks of the new mesothelioma oral medication before beginning treatment. The trial has shown many benefits such as 10% of participants have had tumor shrinkage that persisted up to at least 21 months, longer than almost all treatments currently available. Research on the mesothelioma oral medication trial has proven that participants tolerate the drug well, and there are currently no dose-limiting toxicities.

Some adverse reactions that have occurred so far include swelling in the extremities, fatigue, and nausea. On rare occasions, some participants have experienced albuminuria, an increase in the liver enzymes alanine transaminase and aspartate aminotransferase, and on one occasion, cardiomyopathy. We understand that making the decision to participate in a clinical trial does not come easy. Before signing up, we recommend speaking with your doctor to fully evaluate your individual case to find out if the trial is right for you.

Eligibility Criteria for Mesothelioma Oral Medication Clinical Trial

To qualify for the trial, you must:

  • Have mesothelioma containing an NF2 mutation.
  • Be 18 years or older.
  • Be diagnosed with a metastatic solid tumor or mesothelioma.
  • Have finished all prior therapies up to 2 weeks before beginning the trial.
    Be well enough to walk.

Those excluded from the trial are patients with:

  • Brain metastases
  • Uncontrolled bacterial, viral, or fungal infections
  • HIV, Hepatitis B, or Hepatitis C
  • And women who are pregnant or breastfeeding

If you have been exposed to Asbestos, request a case evaluation for compensation today.
Evaluate My Case

Where is This Mesothelioma Oral Medication Clinical Trial Located?

We understand that signing up for clinical trials can be confusing at times, and we are here to help. At Mesothelioma Hub, our patient advocates can walk you through the process and sign up for the correct location. The trial is currently active for people with mesothelioma in many states, including Illinois, Massachusetts, Minnesota, New York, and Texas.

To contact those conducting the VT3989 Clinical Trial, reach out to one of our patient advocates who will help you navigate the complexities of the trial or inquire at one of the below active trial sites. Our advocates are readily available to support you throughout all phases and talk you through the entirety of the trial, from the screening and consent phase to finding the best treatment and medical centers.

Active Trial Sites:

  • Chicago, Illinois
    • University of Chicago Comprehensive Cancer Center
  • Boston, Massachusetts
    • Massachusetts General Hospital Cancer Center
  • Dana-Farber Cancer Institute
    • Brigham and Women’s Hospital
  • Minneapolis, Minnesota
    • University of Minnesota/Masonic Cancer Center
  • New York, New York
    • Memorial Sloan Kettering Cancer Center
  • Houston, Texas
    • M D Anderson Cancer Center

Signing up for VT3989 Phase 1 Clinical Trail

Researchers are constantly working at advancing mesothelioma treatments and therapies for those suffering from mesothelioma. We recommend clinical trials for people living with chronic illnesses as they may aid in improving the quality of life. Mesothelioma Hub works to connect you with the nation’s top mesothelioma doctors and specialists and provides support for those with mesothelioma and their loved ones. Our patient advocates will provide you with the information and recourses needed to help walk you through the entire process of the trial. Contact us today for help signing up and resources to assist you during the new oral medication trial.

Last updated on March 21st, 2024 at 08:00 pm

Mesothelioma Support Team

Mesothelioma Hub is dedicated to helping you find information, support, and advice. Reach out any time!